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Summary. Background and Objective. Distinction between benign and malignant thyroid tu-
mors is essential for proper clinical management. The aim of this study was to evaluate the diagnos-
tic potential of a set of 3 molecular markers in the differential diagnosis of thyroid tumors. 
Material and Methods. Immunohistochemistry for HBME-1, E-cadherin (E-CAD), and CD56 
was carried out in 36 follicular adenomas, 77 colloid goiters, 36 papillary thyroid carcinomas, and 
14 follicular carcinomas. Sixty-eight thyroid fine needle aspiration (FNA) cases confirmed by sub-
sequent surgical resection specimens were selected. Immunocytochemistry for HBME-1, E-CAD, 
and CD56 was performed in these cases, including 25 papillary thyroid carcinomas, 1 follicular 
carcinoma, 22 follicular adenomas, and 20 colloid goiters.
Results. PTC was characterized by a decreased expression of E-CAD and CD56 contrary to the 
surrounding benign thyroid tissues. There was no HBME-1 expression in benign thyroid tissues, 
but it was high in papillary thyroid carcinomas and weak in follicular adenomas. The expression 
of E-CAD and CD56 was significantly higher in follicular adenomas than in the surrounding 
thyroid tissues. Analyzing the FNA material, HBME-1 expression was documented in 96% of 
papillary thyroid carcinomas, but there was no expression in the benign lesions. E-CAD and CD56 
expression was significantly weakened in papillary thyroid carcinomas, but enhanced in follicular 
adenomas. 
Conclusions. HBME-1 was found only in malignant lesions and can be considered the most 
sensitive, specific single marker in papillary thyroid carcinomas. CD56 and E-CAD can assist in 
the decision-making on the benign and malignant nature of the nodule. Immunocytochemistry is of 
value as an ancillary test to enhance the diagnostic accuracy of thyroid FNA samples.     
Introduction
Thyroid nodules are a very frequent finding, and 
their prevalence steadily increases with age. Nodu-
lar thyroid disease refers to the presence of a solid 
nodule, a multinodular gland, or one or more cystic 
lesions. It is estimated that 5%–7% of adults have 
clinically detectable nodules in the thyroid, and with 
the emergence of modern ultrasonographic (US) 
techniques detecting thyroid nodules of a few mil-
limeters, the frequency of nodularity is estimated to 
be 16%–67% in unselected subjects (1, 2).
Most of the discovered nodules are benign; how-
ever, there were approximately 44 000 estimated new 
cases of thyroid cancer and 1700 estimated deaths in 
the United States in 2010 (3). The annual incidence 
increased from 3.6 per 100 000 in 1973 to 8.7 per 
100 000 in 2002 (2.4-fold increase), and this trend 
appears to be continuing. Mostly it is caused by an 
increase in the incidence of papillary thyroid carci-
noma (PTC), which increased from 2.7 to 7.7 per 
100 000 (2.9-fold increase) (4). More than 80% of 
the malignancies present in palpable thyroid nodules 
are PTC followed by follicular cancer (FC) and sig-
nificantly less frequent anaplastic carcinomas. Thy-
roid cancer accounts for about 1%–2% of all malig-
nancies and 90% of all neuroendocrine tumors (5).
The primary goal in the evaluation of the thyroid 
nodules is to distinguish those nodules that require 
surgical intervention from those that can be safely 
observed. Usually medical concerns according to 
the thyroid nodules revolve around 3 questions: 1) 
the presence of thyroid disfunction; 2) the presence 
of malignancy; and 3) the likelihood of a progressive 
increase in size of the nodule eventually leading to 
symptoms (6). 
Fine needle aspiration (FNA) has become the ul-
timate test in conjunction with clinical findings to 
select those patients who will benefit from surgery 
the most. FNA is now considered the most accu-
rate, cost-effective, and simplest screening method 
for the fast diagnosis of thyroid nodules, with the 
accuracy being around 95% (7). It would be wrong 
to assume that the most precise quality of care is ob-
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tained by evaluating all thyroid nodules with FNA, 
apart from their size and their clinical presence 
(multinodular thyroid, single nodule, age of the pa-
tient, radiation history, etc.), since the probability 
for the presence of cytologically “suspicious” lesions 
is 20%. Considering this, most of the patients will 
eventually undergo a thyroidectomy to exclude the 
presence of cancer, which is present in 10%–20% 
of all microfollicular lesions. Hence, once the deci-
sion is made to do FNA biopsy of the nodule, the 
patient has an a priori probability of 10%–20% for 
a thyroidectomy, which is unnecessary in 80%–90% 
of the cases (6).
The differential diagnosis of thyroid nodules 
could be difficult due to the overlapping morpho-
logical features; therefore, many attempts have been 
described to find the additional criteria to distin-
guish thyroid pathologies in surgical material and in 
less explored FNA cytological specimens. A grow-
ing number of molecular or immunohistochemical 
(IHC) markers are being identified and tested with 
a considerable variability in the outcomes of these 
studies. 
In this study, we evaluated the usefulness of 
applying the panel of 3 IHC markers – HBME-1, 
E-cadherin (E-CAD) and CD56 – on the histologi-
cal samples of various thyroid lesions as well as on 
thyroid FNA samples to determine their diagnos-
tic accuracy in the differential diagnosis of thyroid 
nodules.
Material and Methods
During the first stage of the study, 163 thyroid-
ectomy specimens were selected consecutively from 
the files of the Institute of Pathology, Pauls Stradins 
Clinical University hospital, Riga, Latvia, between 
2006 and 2011. After the histological verification 
of diagnosis, the study group consisted of 50 ma-
lignant and 113 benign thyroid lesions including 36 
PTCs and 14 FCs as well as 36 FAs and 77 colloid 
goiters (CGs). 
The inclusion criteria were as follows: differentiat-
ed thyroid cancer originating from follicular epitheli-
al cells including all types of papillary thyroid cancer 
and follicular cancer, except a Hürthle cell variant; 
unequivocal morphological findings; enough archival 
paraffin-embedded tissue material for analysis; and 
the period from operation to immunohistochemical 
investigation not exceeding 8 years.
During the second stage of the study, 68 thyroid 
FNA cases confirmed by subsequent surgical re-
section specimens during the period of 2010–2011 
were selected from the Institute of Pathology, Pauls 
Stradins Clinical University Hospital, Riga, Latvia. 
The study group consisted of 26 malignant and 42 
benign thyroid lesions including 25 PTC and 1 FC 
as well as 22 FA and 20 cases of CG.
The inclusion criteria in the second stage of the 
study were as follows: available FNA smear as well 
as operation material for the same case according to 
the abovementioned inclusion criteria and the pe-
riod of less than one year from FNA biopsy of the 
thyroid to operation and final morphology.
The institutional Ethics Committee approved the 
study. Written consent was obtained from the pa-
tients before the FNA procedure.
The tissue processing and the general histologi-
cal report were performed as described previously 
by Ozolins et al. (8). During the screening, the ar-
chival diagnoses were verified by the examination 
of these slides by an independent pathologist. The 
diagnostics, typing, and grading of thyroid pathol-
ogy were performed according to the World Health 
Organization Classification of Tumors (9) by an in-
dependent reviewer experienced in thyroid pathol-
ogy. Only cases with an unequivocal histological di-
agnosis were included in the study group.
For immunophenotypic studies, formalin-fixed 
and paraffin-embedded tissue specimens were cut 
in 3-μm-thick sections on electrostatically charged 
Histobond glass slides and incubated at 60°C for 
1 hour to ensure the tissue adhesion to the slides. 
Deparaffining and rehydration were carried out by 
routine treatment in xylene for 4×5 minutes and 
graded ethanol for 2×3 minutes (99.9%), 4×3 min-
utes (96%), and 5 min (70%). Endogenous peroxi-
dase activity was blocked by 0.5% hydrogen perox-
ide in methanol for 10 minutes. All chemicals were 
produced by Sigma-Aldrich (Steinheim, Germany).
After rinsing in the TBS buffer (pH 7.6, Tris-
buffered saline, THAM-HCl 50 mmol/L, NaCl 
150 mmol/L) for 5 minutes, the slides were subject-
ed to heat-induced antigen retrieval (HIER) treat-
ment in a domestic microwave oven for 3×5 minutes 
at maximum power in basic buffer (TEG, pH 9.0, 10 
mmol/L Tris base, 0.5 mmol/L EGTA). After the 
HIER, the slides were allowed to cool at room tem-
perature for 20 minutes in the HIER buffer.
The slides were encircled with a Dako pen (Dako, 
Glostrup, Denmark) and transferred to magnetic 
immunostaining trays (CellPath plc, Newtown, 
UK). After the rinse with TBS buffer for 5 minutes, 
the incubation with primary antibodies was carried 
out at room temperature for 60 minutes. The fol-
lowing monoclonal antibodies were used: HBME-1 
(clone HBME-1; 1:50; Dako, Glostrup, Denmark), 
E-CAD (clone NCH-38; 1:50 Dako, Glostrup, 
Denmark), and CD56 (clone 123C3; 1:100; Dako, 
Glostrup, Denmark). 
Unbound primary antibodies later were removed 
by repeated rinses with TBS buffer for 2×5 min-
utes. A commercially available polymeric EnVi-
sion+ System, bound with horseradish peroxidase 
(Dako), was used for visualization. The slides were 
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incubated in a humid chamber for 30 minutes with 
EnVision+ with following rinses in TBS for 2×5 
minutes. The color developed after incubation with 
3,3-diaminobenzidine (Dako) for 10 minutes. The 
slides then were rinsed in water and counterstained 
with hematoxylin for 3 minutes. After color devel-
opment in tap water for 5 minutes, the slides were 
cover-slipped using an aqueous mounting medium 
Faramount (Dako). The slides of positive and nega-
tive control were included in each run.
The membranous expression of HBME-1, E-
CAD, and CD56 was scored semiquantitatively by 
the intensity of staining and percentage of positive 
cells. The staining intensity was estimated as nega-
tive (0), weakly positive (1), moderately positive 
(2), or positive (3). To evaluate the expression of 
the considered markers in the entire analyzable tis-
sue, the expression intensity was computed as the 
multiplication of the percentage of positive cells by 
staining intensity. The lesion was considered posi-
tive for a marker when the expression intensity was 
at least 1.5.
Fine Needle Aspiration and Immunocytochemistry. 
US followed by FNA was performed by one experi-
enced radiologist using a GE Voluson E8 ultrasound 
machine and a 11L-D linear transducer at the Insti-
tute of Diagnostic Radiology, Pauls Stradins Clini-
cal University Hospital, Riga, Latvia. 
In case of a single thyroid nodule, only nodules 
greater than 1 cm were further evaluated by FNA. In 
a multinodular gland, either the dominant nodule 
or the nodule with the most suspicious US findings 
was evaluated. The following US characteristics as-
sociated with a higher risk of malignancy were con-
sidered: marked hypoechogenicity compared with 
normal thyroid parenchyma, microcalcifications, 
irregular or microlobulated margins, increased in-
tranodular vascularity, and a elongated shape char-
acterized by higher height exceeding width.
During the FNA procedure, patients were placed 
in the supine position; the puncture site was pre-
pared under sterile conditions and draped. A US 
probe was covered under sterile conditions and dis-
infected with a Cutasept F solution. Lidocaine, a 
local anesthetic (1.0 mL, 20 mg/mL), was used. A 
21-gauge needle was attached to a 20-mL syringe. 
Under the real-time visualization, the needle tip was 
introduced into suspicious nodules. To generate an 
appropriate negative pressure, the sucker of syringe 
was pulled out for 5–10 mL. A minimum of 2 pass-
es was employed. The placement of the needle was 
documented by taking pictures. The aspirated ma-
terial was placed, smeared on Histobond adhesive 
glass slides, and air-dried. 
For immunophenotypic studies, the cell smears 
were air-dried and fixed in 96% ethanol for 10 min-
utes. Further immunophenotypic testing was done 
as described previously. 
The statistical evaluation of the data was carried 
out using the Statistical Package for Social Sciences 
(SPSS® version 17.0) and Microsoft® Excel for 
Mac 2011 programs. In the present study, descrip-
tive statistics was used as well as 95% confidence 
interval for a single proportion and a mean as de-
scribed by Altman et al. (10). The calculations of 
confidence intervals were made by the Confidence 
Interval Analysis (CIA) software. The sensitivity, 
specificity, positive predictive value (PPV), and 
negative predictive value (NPV) were calculated as 
described by Altman et al. (10).
Results
The results of immunohistochemical staining in 
benign and malignant thyroid lesions are summa-
rized in Table 1. The expression of HBME-1 was 
absent in benign thyroid lesions including FA, CG, 
and pericancerous tissue, but was notably high in 
PTC (Fig. 1) with a mean intensity of 2.80 (95% CI, 
2.68–2.91) and FC (Fig. 2) with a mean intensity 
of 0.90 (95% CI, 0.09–1.70). To distinguish PTC 
from the tissue surrounding PTC, the sensitivity, 
specificity, PPV, and NPV for HBME-1 was 1.00. 
To differentiate FA from PTC, the sensitivity, spec-
ificity, PPV, and NPV were 1.00, 0.96, 0.96, and 
1.00, respectively. HBME-1 had an extremely high 
value in the differential diagnostics of PTC show-
ing a high ability to discriminate between PTC and 
benign tissues. 
The expression of E-CAD was significantly 
higher in FA than in the surrounding thyroid tis-
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FA, follicular adenoma; TtS FA, thyroid tissue surrounding FA; PTC, papillary thyroid carcinoma; 
TtS PTC, thyroid tissue surrounding PTC; CG, colloid goiter; FC, follicular cancer; CI, confidence interval.
Table 1. Intensity of Immunohistochemical Marker Expression in Thyroid Lesions
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Fig. 1. Morphologic structure and immunophenotype of follicular adenoma (A–C) in contrast to papillary thyroid carcinoma (D–F)
A, tissue structure of follicular adenoma. Note the presence of capsule (hematoxylin-eosin [HE], original magnification [OM] 
×100); B, lack of HBME-1 in follicular adenoma (immunoperoxidase (IP), anti-HBME-1, OM ×100); C, intense expression of 
CD56 in follicular adenoma (IP, anti-CD56, OM ×100); D, tissue structure of papillary thyroid carcinoma. Note the character-
istic architecture and nuclear structure (HE, OM ×100); E, intense expression of HBME-1 in papillary thyroid cancer (IP, anti-








sion of E-CAD and CD56 was observed in 8% (95% 
CI, 1.40%–27.5%) and 4% (95% CI, 0.21%–22.3%) 
of PTC cases, respectively. Regarding CG (n=20), 
10% and 5% of cases were positive for E-CAD and 
CD56, respectively.
Discussion
Thyroid nodules are common lesions in clinical 
practice, but only a minority is malignant or sus-
picious tumors that require surgery. As early as in 
1982, it was stated that FNA is the most sensitive 
and specific test for the diagnosis of thyroid nodules. 
In fact, the present consensus is that thyroid FNA 
biopsy is the procedure of choice for evaluation of 
nodules therefore cytologic interpretation can play a 
very important role in further clinical management 
of the patient. There are well-known limitations in 
the role of thyroid FNA, most importantly its in-
ability to differentiate benign from malignant fol-
licular neoplasms, since this diagnosis rests on the 
histologic identification of capsular and/or vascular 
invasion (11, 12). Immunohistochemistry was in-
troduced to the practice of pathology in the early 
1970s; however, in a thyroid pathology, originally 
its use is restricted. New techniques have been intro-
duced to the thyroid FNA procedure to enhance its 
diagnostic value and improve the accuracy. Despite 
these improvements, many authors have concluded 
that even in “the right hands,” the rate of inadequate 
smears is rarely lower that 10% and there remain 
difficulties in the cytologic diagnosis of follicular-
derived lesions. For this reason, the characterization 
of follicular thyroid nodules is widely considered 
as the “gray zone of FNA cytology.” Much atten-
tion has shifted to the identification of molecular or 
IHC markers that can help distinguish adenomatous 
colloid nodules or a follicular adenoma from a fol-
licular carcinoma on the one hand and PTC from a 
follicular neoplasm on the other hand (13). 
The diagnosis of PTC in FNA specimens is usu-
ally unsophisticated when classic cytologic features 
are present. However, in clinical practice, often it is 
difficult to make an unequivocal cytologic diagnosis 
of PTC. The diagnostic difficulties are related to the 
observation that some of typical cytologic features of 
PTC (nuclear grooves, giant cells, psammoma bod-
ies, and papillary fragments) can also be observed 
in nonneoplastic lesions and follicular neoplasms of 
the thyroid (14). 
During the last several years, a large number of 
IHC markers have been tested in histologic samples 
and, to a lesser extent, in FNA samples with vari-
able success rates. The evaluation of IHC markers 
was mostly preformed in surgically resected thyroid 
specimens. However, similar studies were also done 
on FNA cytologic specimens using cellblock prepa-
rations (15, 16). In general, the studies have shown 
similar results of markers expression comparing 
surgical specimens and FNA cellblock sections. 
According to the published studies, many IHC 
markers have been investigated for the evaluation 
of thyroid nodules. However, only few markers have 
emerged as potentially useful for differentiating be-
nign from malignant thyroid nodules. Considering 
this information, we chose to test these most prom-
ising markers (HBME-1, CD56, and E-CAD) on 
histological samples of benign and malignant thy-
roid lesions. Within the next step of our study, we 
tested the possibility to use these markers for the 
evaluation of FNA cytology material of the thyroid. 
Anti-HBME-1, first described in 1992 by Batti-
fora et al., is a monoclonal antibody directed against 
an antigen of the microvillous surface of mesotheli-
oma cells (17). Most studies using HBME-1 for the 
diagnosis of thyroid tumors have been performed 
in tissue samples, and only few studies using FNA 
products have been carried out in cellblocks or thin 
layers (18, 19). Our findings showed that PTCs had 
a high-level immunoexpression of HBME-1 and 
FC had a weak expression in the tissue samples. A 
high level of HBME-1 immunoexpression was also 
documented in the FNA samples. Unfortunately, 
there was only one case of FC in the FNA study 
group. No HBME-1 immunoexpression was ob-
served in benign lesions. This agrees with the study 
by Nasr et al. (20), who reported HBME-1 to be the 
most sensitive and specific marker, staining 96% of 
PTCs, whereas normal thyroid tissues were consist-
ently negative for HBME-1. A study by Saleh et al. 
(21) showed that the sensitivity and specificity of 
immunoexpression for HBME-1 to distinguish be-
nign from malignant lesions was one of the highest 
among all the markers tested (88.9% versus 72.7%, 
respectively). Several recent investigators have re-
ported a high expression of HBME-1 in PTCs and 
some FCs, but a low or negative expression in FAs 
(20, 21). 
E-CAD is a transmembrane glycoprotein, which 
is present in most epithelial cells and appears to play 
an important role in epithelial integrity, cell adhe-
sion and differentiation, and the maintenance of 
cell polarity and tissue architecture. Its impairment 
correlates with the development and progression of 
human carcinomas. The expression of E-CAD in 
the  normal thyroid was first described by Eidelman 
et al. (22). Since then, it is known that a decrease 
in the E-CAD expression is associated with thyroid 
neoplasms (23). In our study, PTCs demonstrated 
a significant reduction in the E-CAD expression 
when compared with FAs or the thyroid tissue sur-
rounding PTCs. In contrast, FCs showed no signifi-
cant differences in the E-CAD expression compared 
Arturs Ozolins, Zenons Narbuts, Ilze Strumfa, et al.
513
Medicina (Kaunas) 2012;48(10)
with FAs. As mentioned before, in the second stage 
of the study, there was only one case of FC to ana-
lyze. The low and heterogenous expression of E-
CAD in PTCs confirms the results of Soares et al. 
(24) and Mitselou et al. (25), who observed a re-
duction of E-CAD expression in PTC compared to 
normal thyroid tissue. Contrary to the abovemen-
tioned studies as well as to our study, Smyth et al. 
demonstrated a significant reduction in the E-CAD 
expression in FCs compared with FAs, but no sig-
nificant decrease in expression in case of PTCs (26). 
CD56 is a neural cell adhesion molecule that is 
present on follicular epithelial cells of the normal 
thyroid (27). Our results showed a positive immu-
noexpression of CD56 in thyroid lesions and tumors 
except for PTCs where it was remarkably decreased. 
These findings are very similar to the results report-
ed by Scarpino et al. showing a low or no expres-
sion of CD56 in PTCs using immunohistochemis-
try (28). Using the immunocytochemical staining of 
CD56, our results showed its expression mainly in 
FA. El Demellawy et al. showed CD56 as an ex-
tremely useful marker in the distinction between 
PTCs and follicular lesions or neoplasms. According 
to their results, a diffuse expression of CD56 was 
present in normal and neoplastic follicular epithe-
lium, but was absent in PTCs (29, 30).
Conclusions
Both in the histological evaluation of formalin-
fixed, paraffin-embedded tissues and in the cyto-
logical examination of FNA, an intense positive 
reaction of HBME-1 was observed only in malig-
nant lesions. CD56 and E-CAD can assist in the 
decision-making about the benign and malignant 
nature of aspirated material. The panel consisting 
of 3 immunohistochemical markers – HBME-1, E-
CAD, and CD56 – can aid both FNA diagnostics 
and evaluation of surgically removed thyroid tissue 
and can be recommended as an adjunct to morpho-
logical criteria. 
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